Cannabidiol (CBD)
There has been a resurgence of interest in Cannabinoids for use as potential pharmaceutical treatments. There are at least 113 different cannabinoids isolated from cannabis, exhibiting varied effects.(1) The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis.(2)(3) Cannabidiol (CBD) is another major constituent of the cannabis plant.(4)

Cannabidiol (CBD) possesses medicinal and therapeutic properties. Unlike tetrahydrocannabinol, CBD does not cause intoxication or euphoria, two unwanted side-effects for medicines. In light of CBD’s medicinal applications and the absence of psychoactive side-effects, demand for GMP-grade CBD from pharmaceutical companies has increased extensively in recent years.(5)

CBD is under investigation as a potential therapeutic treatment for various illnesses and diseases, including multiple cancers, seizures, dermatological conditions and anxiety. As of 1st November 2018, specialist doctors can prescribe cannabis-based products for medicinal use in humans which fall within schedule 2 to the Misuse of Drugs Regulations 2001 without requiring a Home Office licence to lawfully write a prescription.(6)

If your company is researching the medicinal properties of CBD or other cannabinoids? Tepnel Phama Services hold schedules 2, 3, 4 part I, 4 part II and schedule 5 controlled drugs licenses. Along with experience and capabilities in testing Cannabinoid formulations, Tepnel Pharma Services supports the Pharmaceutical Research and Development from preclinical enabling stability and formulation selection through to batch release testing into the market place.

At Tepnel we focus on the provision of pharmaceutical testing in support of drug development with an emphasis on inhalation, oral dosage, parenteral and biologics. Our people are committed to providing laboratory services that deliver on the promise of quality, through a highly skilled workforce and a customer focused performance, working alongside you towards a common goal. Our cGMP pharmaceutical testing facility is located in Livingston, Scotland where we work together with our customers and partners building mutual trust through a sharing of knowledge, expertise and teamwork. Our services include:

• Lot and batch release testing
• ICH stability testing and storage
• Raw materials testing
• Pharmacopeial testing
• ICH method development and validation

To find out how partnering with Tepnel can reduce cost and accelerate your drug development programme please contact:

Primary Contact:
Stewart Neithercut, Business Development Manager
Email: stewart.neithercut@hologic.com
Mobile : +44 (0) 7785 438 308
Office : +44 (0) 1506 424 270
Website: http://www.tepnelpharmaservices.com

1. Pacher P, Bátkai S, Kunos G (September 2006). “The endocannabinoid system as an emerging target of harmacotherapy”. Pharmacological Reviews. 58 (3)
2. Lambert DM, Fowler CJ (August 2005). “The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications”. Journal of Medicinal Chemistry. 48(16): 5059–87
3. Pertwee, Roger, ed. (2005). Cannabinoids. Springer-Verlag. p. 2. ISBN 978-3-540-22565-2.
4. “Bulletin on Narcotics – 1962 Issue 3 – 004”. UNODC (United Nations Office of Drugs and Crime). 1962-01-01. Retrieved 2014-01-15.
5. Manufacturing Chemist news article page – JM to offer a new process to synthesise CBD
6. Gov UK guidance controlled drugs